Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc (ACAD) delivers innovative therapies for central nervous system disorders and rare diseases through targeted research and clinical development. This dedicated news hub provides investors and healthcare professionals with essential updates on ACAD's progress in neurology and neuro-rare disease treatments.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Parkinson's Disease Psychosis therapies, Rett syndrome research advancements, and pipeline progress across ACAD's neuroscience portfolio. Each release maintains scientific rigor while remaining accessible to both medical experts and investment analysts.
Key coverage areas include FDA submissions, peer-reviewed study publications, and collaborative research initiatives. Bookmark this page for centralized access to ACAD's latest scientific achievements and operational updates, carefully vetted for accuracy and relevance to long-term therapeutic development.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has published new data from an open-label extension study regarding the efficacy of NUPLAZID for treating hallucinations and delusions in patients with Parkinson’s disease psychosis (PDP). The study revealed sustained efficacy for patients previously on a 34 mg dose of NUPLAZID from Weeks 6 to 10. Approximately 50% of Parkinson’s patients may experience these troubling symptoms, which can significantly impact quality of life. The findings reinforce NUPLAZID's position as a critical first-line therapy for PDP.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced the publication of open-label extension (OLE) data showing sustained efficacy of NUPLAZID (34 mg) for treating hallucinations and delusions in Parkinson's disease psychosis (PDP). Patients previously on lower doses demonstrated improvement after switching to NUPLAZID. The OLE study involved 459 patients, of which 424 were assessed, revealing significant symptom improvements. Adverse events were reported by 46.8% of patients, mostly mild, with some serious cases. This data reinforces NUPLAZID's role as a first-line therapy for PDP.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced its participation in two upcoming virtual investor conferences. The Jefferies 2021 Virtual Healthcare Conference will feature a fireside chat on June 2, 2021, at 1:30 p.m. ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 2:10 p.m. ET. Live webcasts of both presentations will be available on Acadia's website, with archived recordings accessible for one month post-event. Acadia is focused on neurological solutions, including therapies for Parkinson's disease psychosis and dementia-related psychosis.
Acadia Pharmaceuticals reported Q1 2021 financial results with net sales of NUPLAZID (pimavanserin) at $106.6 million, an 18% increase year-over-year. The company faces challenges, having received a Complete Response Letter from the FDA regarding its sNDA for dementia-related psychosis. R&D expenses decreased to $57 million, while SG&A expenses rose to $111.7 million. Acadia reiterated NUPLAZID net sales guidance of $510-$550 million but revised R&D and SG&A guidance downwards, reflecting strategic adjustments. The company had a net loss of $66.4 million for the quarter.
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in two upcoming virtual investor conferences. The BofA Securities 2021 Health Care Conference is on May 12, 2021, at 2:45 p.m. ET, followed by the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 3:05 p.m. ET. Live webcasts will be available on the company's website, with archived recordings accessible for about a month afterward. Acadia focuses on advancing neuroscience solutions for conditions like Parkinson's disease psychosis and dementia-related psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) will release its first quarter 2021 financial results on May 5, 2021, after U.S. market close. A conference call to discuss these results will take place at 5:00 p.m. ET the same day. Participants can join by phone or via a live webcast on Acadia's website, with a replay available until May 19, 2021. Acadia is focused on advancing neuroscience solutions, including treatments for Parkinson's disease psychosis and dementia-related psychosis, and is engaged in late-stage development for several mental health conditions.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has received a Complete Response Letter (CRL) from the FDA for its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) aimed at treating hallucinations and delusions in dementia-related psychosis (DRP). The FDA cited insufficient statistical significance in certain dementia subgroups and a lack of substantial evidence for effectiveness. Acadia intends to request a Type A meeting with the FDA to discuss the CRL and potential approval pathways. No safety concerns were raised in the CRL.
Acadia Pharmaceuticals announced on March 3, 2021, that it received an FDA notification identifying deficiencies in its supplemental New Drug Application (sNDA) review, inhibiting discussions on labeling and post-marketing requirements. The notification lacks specific details on the deficiencies, and the company aims to clarify these issues with the FDA. The FDA had previously set a PDUFA action date of April 3, 2021, for the sNDA review.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) reported strong financial results for Q4 2020, with net sales of NUPLAZID reaching $121 million, a 23% increase from Q4 2019. For the full year, net product sales grew 30% to $441.8 million. However, the company incurred a net loss of $66.8 million for Q4 and $281.6 million for the year. Acadia anticipates net sales of $510-$550 million for NUPLAZID in 2021 but withheld guidance for dementia-related psychosis revenue. Strategic advances include multiple Phase 3 studies and a new FDA label for NUPLAZID.
Acadia Pharmaceuticals has launched MoreThanMemoryLoss.com, an educational website aimed at assisting caregivers and individuals living with dementia. The site offers resources about dementia-related hallucinations and delusions, a common challenge for about 30% of the 8 million people with dementia in the U.S. The initiative was developed with input from caregivers and advocacy groups, featuring guides and personal stories to encourage discussions between caregivers and healthcare providers. This resource aims to address the distressing symptoms of dementia-related psychosis.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
